<DOC>
	<DOCNO>NCT02366195</DOCNO>
	<brief_summary>The study phase 2 , multi center , single arm study design evaluate correlation CD8+ cell density objective response rate subject unresected stage IIIB IVM1c melanoma . This study also evaluate safety tolerability profile talimogene laherparepvec .</brief_summary>
	<brief_title>Single-arm Trial Evaluate Role Immune Response Talimogene Laherparepvec Unresected Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>1 . Provided informed consent prior initiation studyspecific activities/procedures 2 . Subject stage IIIB IVM1c melanoma surgery recommend 3 . Candidate intralesional therapy 4 . Measurable disease great diameter â‰¥ 10 mm 5 . ECOG performance status 0 1 6 . Adequate organ function Other Inclusion Criteria May Apply 1 . Clinically active cerebral metastasis . 2 . Bone metastases 3 . Primary ocular mucosal melanoma 4 . Active herpetic skin lesion prior complication HSV1 infection ( eg , herpetic keratitis encephalitis ) 5 . Requires intermittent chronic systemic ( intravenous oral ) treatment antiherpetic drug ( eg , acyclovir ) , intermittent topical use 6 . Female subject pregnant breastfeeding , plan become pregnant study treatment 3 month last dose talimogene laherparepvec 7 . Female subject childbearing potential unwilling use acceptable method ( ) effective contraception Other Exclusion Criteria May Apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>T-VEC</keyword>
	<keyword>CD8+ cell density</keyword>
	<keyword>objective response rate</keyword>
	<keyword>unresected</keyword>
	<keyword>Melanoma</keyword>
</DOC>